Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lonquex

- PMLiVE

Key Teva shareholder backs Vigodman as next CEO

Board director tipped to replace Jeremy Levin at Israeli pharma firm

- PMLiVE

Teva’s vice chair steps down

Amir Elstein to take over from Moshe Many

- PMLiVE

Teva expects big things from improved drug programme

Aims to market enhanced versions of existing medicines

- PMLiVE

Teva withdraws US filing for cancer biologic

FDA requests more data for balugrastim

- PMLiVE

Change at the top as Levin leaves Teva

CEO resigns amid company-wide restructure

- PMLiVE

Union pressure delays Teva’s Israeli layoffs

Workforce cuts put on hold

- PMLiVE

Teva cuts 5,000 jobs to save $2bn a year by 2017

Israeli pharma company accelerates cost-reduction plans

- PMLiVE

Teva defends Copaxone from Dutch patent challenge

Halts Mylan from marketing generic copy of MS drug

- PMLiVE

Teva signs R&D alliance to pursue novel cancer drugs

Will work with Cancer Research on first-in-class oncology treatments

- PMLiVE

Teva halts development of Nuvigil in bipolar disorder

Shelves plan to expand use of sleep disorder therapy

Teva Pharma logo

Neulasta rival from Teva cleared in EU

Lonquex offers competition to Amgen drug in neutropaenia

- PMLiVE

UK court upholds Teva’s patent on Copaxone

Dismisses challenge from Mylan

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links